Chardan Capital Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price target from $75 to $72.
Chardan Capital analyst Keay Nakae downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price target from $75 to $72.